397 related articles for article (PubMed ID: 17890957)
1. Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
Mahieu B; Jacobs N; Mahieu S; Naelaerts K; Vertessen F; Weyler J; Jacquemyn Y; Van der Planken M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR
Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487
[TBL] [Abstract][Full Text] [Related]
3. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C.
De Mitrio V; Marino R; Cicinelli E; Galantino P; Di Bari L; Giannoccaro F; De Pergola G; Lapecorella M; Schonauer S; Schiraldi O
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):175-82. PubMed ID: 10759011
[TBL] [Abstract][Full Text] [Related]
5. Endothelial cell activation and hypercoagulability in ocular Behçet's disease.
Probst K; Fijnheer R; Rothova A
Am J Ophthalmol; 2004 May; 137(5):850-7. PubMed ID: 15126149
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy.
Clark P; Brennand J; Conkie JA; McCall F; Greer IA; Walker ID
Thromb Haemost; 1998 Jun; 79(6):1166-70. PubMed ID: 9657443
[TBL] [Abstract][Full Text] [Related]
7. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
8. A prothrombinase-based assay for detection of resistance to activated protein C.
Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
[TBL] [Abstract][Full Text] [Related]
9. APC resistance and other haemostatic variables during pregnancy and puerperium.
Kjellberg U; Andersson NE; Rosén S; Tengborn L; Hellgren M
Thromb Haemost; 1999 Apr; 81(4):527-31. PubMed ID: 10235433
[TBL] [Abstract][Full Text] [Related]
10. Endotoxaemia induces resistance to activated protein C in healthy humans.
de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vlasuk GP; Rote WE; Levi M; Büller HR; Meijers JC
Br J Haematol; 2006 Jul; 134(2):213-9. PubMed ID: 16846480
[TBL] [Abstract][Full Text] [Related]
11. Detection of decreased response to activated protein C during pregnancy by an endogenous thrombin potential-based assay.
Sugimura M; Kobayashi T; Kanayama N; Terao T
Semin Thromb Hemost; 1999; 25(5):497-502. PubMed ID: 10625209
[TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
13. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance.
Clark P; Sattar N; Walker ID; Greer IA
Thromb Haemost; 2001 Jan; 85(1):30-5. PubMed ID: 11204583
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.
Koedam JA; Meijers JC; Sixma JJ; Bouma BN
J Clin Invest; 1988 Oct; 82(4):1236-43. PubMed ID: 2971673
[TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
Toulon P
Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
17. [Hereditary disorders of the protein C system in central artery and branch arteriolar occlusions].
Greiner K; Hafner G; Prellwitz W; Pfeiffer N
Klin Monbl Augenheilkd; 1999 Jul; 215(1):33-6. PubMed ID: 10448635
[TBL] [Abstract][Full Text] [Related]
18. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual consistency of the activated protein C resistance phenotype.
Tosetto A; Simioni M; Madeo D; Rodeghiero F
Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
[TBL] [Abstract][Full Text] [Related]
20. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Tchaikovski SN; Thomassen MC; Costa SD; Peeters LL; Rosing J
Thromb Haemost; 2011 Nov; 106(5):914-21. PubMed ID: 21979881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
